Dziesięć powodów, dla których warto stosować atorwastatynę Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2014
Słowa kluczowe:
hiperlipidemia, atorwastatyna, leczenie hipolipemizujące
##plugins.themes.bootstrap3.article.main##
Abstrakt
W pracy przedstawiono 10 powodów, dla których warto przepisać choremu atorwastatynę. Wymieniono grupy pacjentów, którzy szczególnie skorzystają na takim leczeniu hipolipemizującym. Odniesiono się przede wszystkim do dowodów pochodzących z dużych, randomizowanych badań klinicznych, na podstawie których eksperci, m.in. Europejskiego Towarzystwa Kardiologicznego (ESC), formułowali aktualne wytyczne postępowania u chorych z chorobami sercowo-naczyniowymi.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Możeńska , O. (2014). Dziesięć powodów, dla których warto stosować atorwastatynę . Medycyna Faktów , 7(3(24), 31-34. Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/2350
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Armitage J.: The safety of statins in clinical practice. Lancet 2007; 370(9601): 1781-1790.
2. European Association for Cardiovascular & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32(14): 1769-1818.
3. Pasceri V., Patti G., Nusca A. et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110(6): 674-678.
4. Mills E.J., O’Regan C., Eyawo O. et al.: Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European Heart Journal 2011; 32(11): 1409-1415.
5. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
6. Sever P.S., Poulter N.R., Dahlof B. et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo- Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151-1157.
7. Sever P.S., Dahlof B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
8. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2007; 28(12): 1462-1536.
9. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004; 350(15): 1495-1504.
10. Aung P.P., Maxwell H.G., Jepson R.G. et al.: Lipid-lowering for peripheral arterial disease of the lower limb. The Cochrane database of systematic reviews 2007(4): CD000123.
11. European Stroke O., Tendera M., Aboyans V., Bartelink M.L. et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(22): 2851-2906.
12. Amarenco P., Labreuche J.: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology 2009; 8(5): 453-463.
13. Elis A., Zhou R., Stein E.A.: Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiology in the Young 2014; 24(3): 437-441.
14. Lario F.C., Miname M.H., Tsutsui J.M. et al.: Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis. Echocardiography 2013; 30(1): 64-71.
15. Wu C.K., Yang Y.H., Lin T.T. et al.: Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. Journal of Internal Medicine 2014.
2. European Association for Cardiovascular & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 2011; 32(14): 1769-1818.
3. Pasceri V., Patti G., Nusca A. et al.: Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2004; 110(6): 674-678.
4. Mills E.J., O’Regan C., Eyawo O. et al.: Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. European Heart Journal 2011; 32(11): 1409-1415.
5. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-696.
6. Sever P.S., Poulter N.R., Dahlof B. et al.: Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo- Scandinavian Cardiac Outcomes Trial – lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28(5): 1151-1157.
7. Sever P.S., Dahlof B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361(9364): 1149-1158.
8. Mancia G., De Backer G., Dominiczak A. et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 2007; 28(12): 1462-1536.
9. Cannon C.P., Braunwald E., McCabe C.H. et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. The New England Journal of Medicine 2004; 350(15): 1495-1504.
10. Aung P.P., Maxwell H.G., Jepson R.G. et al.: Lipid-lowering for peripheral arterial disease of the lower limb. The Cochrane database of systematic reviews 2007(4): CD000123.
11. European Stroke O., Tendera M., Aboyans V., Bartelink M.L. et al.: ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal 2011; 32(22): 2851-2906.
12. Amarenco P., Labreuche J.: Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurology 2009; 8(5): 453-463.
13. Elis A., Zhou R., Stein E.A.: Treatment of familial hypercholesterolaemia in children and adolescents in the last three decades. Cardiology in the Young 2014; 24(3): 437-441.
14. Lario F.C., Miname M.H., Tsutsui J.M. et al.: Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis. Echocardiography 2013; 30(1): 64-71.
15. Wu C.K., Yang Y.H., Lin T.T. et al.: Statin use reduces the risk of dementia in elderly patients: a nationwide data survey and propensity analysis. Journal of Internal Medicine 2014.